Combination antidepressant therapy for major depressive disorder: Speed and probability of remission

Journal of Psychiatric Research

Volumn 52, Issue 1, 2014, Pages 7-14

  Stewart, Jonathan W ^a,b   McGrath, Patrick J ^a,b   Blondeau, Claude ^c   Deliyannides, Deborah A ^b   Hellerstein, David ^a,b   Norris, Sandhaya ^c   Amat, Jose ^a,b   Pilowsky, Daniel J ^a,b   Tessier, Pierre ^c   Laberge, Louise ^d   O'Shea, Donna ^b   Chen, Ying ^b   Withers, Amy ^b   Bergeron, Richard ^d   Blier, Pierre ^c  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c ROYAL OTTAWA HOSPITAL   (Canada)

^d Centre Hospitalier Pierre Janet   (Canada)

Author keywords

Bupropion; Combination treatment; Escitalopram; Major depression; Remission

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TREATMENT RESPONSE; YOUNG ADULT; ADOLESCENT; ANALYSIS OF VARIANCE; CANADA; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOLLOW UP; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; RECURRENT DISEASE; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BUPROPION; CANADA; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84895868830     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.12.001     Document Type: Article

References (32)

1. Andrews J.M., Ninan P.T., Nemeroff C.B. Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 1996, 4:48-56.
2. Ascher J.A., Cole J.O., Colin J.-N., Feighner J.P., Fibiger H.C., Golden R.N., et al. Bupropion: a review of its mechanism of antidepressant activity. JClin Psychiatry 1995, 56:395-401.
3. Blier P., Gobbi G., Turcotte J.E., de Montigny C., Boucher N., Hébert C., et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009, 19:457-465.
4. Blier P., Ward H.E., Tremblay P., Laberge L., Hébert C., Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167:281-288.
5. Bræstrup C., Sanchez C. Escitalopram: a unique mechanism of action. Int J Psychiatry in Clin Pract 2004, 8:11-13.
6. Cozza K.L., Armstrong C. Concise guide to the cytochrome P450 system: drug interaction principles for medical practice 2001, 216. American Psychiatric Publishing, Washington, DC.
7. Derivan A., Entsuah A.R., Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995, 31:439-447.
8. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. User's guide for the structured clinical interview for DSM-IV Axis I disorders (SCID-I) 2002, American Psychiatric Press, Washington, D.C.
9. ECDEU Assessment manual for psychopharmacology: publication ADM 76-338 1976, 218-222. US Department of Health, Education, and Welfare, Washington, DC. W. Guy (Ed.).
10. Hamilton M. Arating scale for depression. JNeurol Neurosurg Psychiatry 1960, 23:56-60.
11. Henkel V., Seemüller F., Obermeier M., Adli M., Bauer M., Mundt C., et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression?. JAffect Disord 2009, 115:439-449.
12. Hordern A. The antidepressant drugs. NEngl J Med 1965, 292:1159-1169.
13. Kasper S., Spadone C., Verpilat P., Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006, 21:105-110.
14. Klerman G.L., Cole J.O. Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965, 17:101-141.
15. Leuchter A.F., Lesser I.M., Trivedi M.H., Rush A.J., Morris D.W., Warden D., et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. JPsychiatr Pract 2008, 14:271-280.
16. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986, 22:343-381.
17. Mitchell A.J. Two-week delay in onset of action of antidepressants: new evidence. Br J Psychiatry 2006, 188:105-106.
18. Montgomery S., Asberg M. Anew depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
19. Nelson J.C., Mazure C.M., Bowers M.B., Jatlow P.I. Apreliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991, 48:303-307.
20. Nelson J.C., Mazure C.M., Jatlow P.I., Bowers M.B., Price L.H. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004, 55:296-300.
21. Papakostas G.I., Perlis R.H., Scalia M.J., Petersen T.J., Fava M. Ameta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. JClin Psychopharmacol 2006, 26:56-60.
22. Papakostas G.I., Petersen T., Sklarsky K.G., Nierenberg A.A., Alpert J.E., Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res 2007, 149:195-200.
23. Posternak M.A., Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. JClin Psychiatry 2005, 66:148-158.
24. Quitkin F.M., Rabkin J.D., Markowitz J.M., Stewart J.W., McGrath P.J., Harrison W. Use of pattern analysis to identify true drug response: a replication. Arch Gen Psychiatry 1987, 44:259-264.
25. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., Arnow B., Klein D.N., et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003, 54:573-583.
26. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
27. Stassen H.H., Delini-Stula A., Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993, 3:127-135.
28. Stewart J.W., McGrath P.J., Deliyannides D.A., Quitkin F.M. Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?. JPsychiatr Pract 2009, 15:337-345.
29. Stimmel G.L., Dopheide J.A., Stahl S.M. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997, 17:10-21.
30. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. JClin Psychiatry 2009, 70:344-353.
31. Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol Clin Exp 2002, 17(Suppl.1):S27-S32.
32. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. STAR*D study team: evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.